Back

Development of a Surface Programmable Activation Receptor system (SPAR): A living cell biosensor for rapid pathogen detection

Kittle, J. D.; Lwande, J. S.; Williams, M. R.; Brody, R.; Frenchmeyer, M.; Hua, J.; Liang, S.; McQuaide, K.; Mo, M.; Neese, A.; Tang, Y.; Vedamoorthy, S.; Zeng, L.; Zupancic, T.; McBrairty, C.

2019-06-30 bioengineering
10.1101/687426 bioRxiv
Show abstract

Efficient pathogen detection is essential for the successful treatment and prevention of infectious disease; however, current methods are often too time intensive to be clinically relevant in cases requiring immediate intervention. We have developed a Surface Programmable Activation Receptor (SPAR) diagnostic platform comprised of universal biosensor cells engineered for use in combination with custom or commercial antibodies to achieve rapid and sensitive pathogen detection. SPAR cells are stably transfected Jurkat T cells designed to constitutively express a modified T cell mouse Fc{gamma}RI receptor on the cell surface and a high level of the luminescent reporter protein aequorin in the cytoplasm. The modified mFc{gamma}RI-CD3{zeta} receptor protein binds with high affinity to the Fc region of any full-length mouse IgG2a and some IgG2 antibodies: this allows customized target detection via the selection of specific antibodies. T-cell receptor aggregation in response to target antigen binding results in signal transduction which, when amplified via the endogenous T cell signal cascade, triggers the rapid intracellular release of calcium. Increased Ca2+ concentrations activate the expressed reporter protein aequorin resulting in the immediate emission of detectable light. Testing demonstrates the accurate and specific detection of numerous targets including P. aeruginosa, E. coli O111, and E. coli O157. We report that the SPAR biosensor cell platform is a reliable pathogen detection method that enables the rapid identification of bacterial causative agents using standard laboratory instrumentation. The technology lends itself to the development of efficient point-of-care testing and may aid in the implementation of effective and pathogen-specific clinical therapies.

Matching journals

The top 2 journals account for 50% of the predicted probability mass.

1
Journal of Immunological Methods
24 papers in training set
Top 0.1%
40.3%
2
PLOS ONE
5266 papers in training set
Top 16%
12.1%
50% of probability mass above
3
Scientific Reports
3612 papers in training set
Top 8%
7.4%
4
Biotechnology and Bioengineering
53 papers in training set
Top 0.2%
4.4%
5
ACS Synthetic Biology
287 papers in training set
Top 0.9%
3.3%
6
Cellular and Molecular Bioengineering
22 papers in training set
Top 0.1%
2.2%
7
Virology
61 papers in training set
Top 0.6%
1.8%
8
Frontiers in Immunology
638 papers in training set
Top 6%
1.5%
9
Vaccines
198 papers in training set
Top 2%
1.1%
10
ACS Omega
105 papers in training set
Top 2%
1.1%
11
New Biotechnology
12 papers in training set
Top 0.2%
1.1%
12
Antibody Therapeutics
16 papers in training set
Top 0.2%
1.1%
13
Cytotherapy
15 papers in training set
Top 0.2%
0.9%
14
Analytical and Bioanalytical Chemistry
18 papers in training set
Top 0.3%
0.9%
15
Cytometry Part A
33 papers in training set
Top 0.3%
0.9%
16
Frontiers in Bioengineering and Biotechnology
98 papers in training set
Top 2%
0.9%
17
Protein Expression and Purification
13 papers in training set
Top 0.1%
0.9%
18
International Journal of Molecular Sciences
494 papers in training set
Top 14%
0.9%
19
Photochemistry and Photobiology
10 papers in training set
Top 0.1%
0.9%
20
BMC Methods
15 papers in training set
Top 0.2%
0.6%
21
Viruses
332 papers in training set
Top 5%
0.6%
22
Biosensors and Bioelectronics
57 papers in training set
Top 0.9%
0.6%
23
Journal of Virological Methods
37 papers in training set
Top 0.5%
0.6%
24
Clinical Chemistry
22 papers in training set
Top 0.4%
0.6%